A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

Ryotaro Bouchi^#¹, Tatsuya Kondo^#², Yasuharu Ohta^#³, Atsushi Goto⁴, Daisuke Tanaka⁵, Hiroaki Satoh⁶, Daisuke Yabe⁷, Rimei Nishimura⁸, Norio Harada^#⁵, Hideki Kamiya^#⁹, Ryo Suzuki^#¹⁰, Toshimasa Yamauchi^#¹¹

Affiliations

¹ Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
² Department of Diabetes, Metabolism and Endocrinology, Kumamoto University Hospital, Kumamoto, Japan.
³ Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
⁴ Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Kanagawa, Japan.
⁵ Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Department of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Chiba, Japan.
⁷ Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
⁸ Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Tokyo, Japan.
⁹ Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Aichi, Japan.
¹⁰ Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo, Japan.
¹¹ Department of Diabetes and Metabolic Diseases, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

^# Contributed equally.

PMID: 36636161
PMCID: PMC9829926
DOI: 10.1007/s13340-022-00605-x

A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

Ryotaro Bouchi et al. Diabetol Int. 2022.

. 2022 Dec 23;14(1):1-14.

doi: 10.1007/s13340-022-00605-x. eCollection 2023 Jan.

Authors

Affiliations

¹ Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan.
² Department of Diabetes, Metabolism and Endocrinology, Kumamoto University Hospital, Kumamoto, Japan.
³ Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
⁴ Department of Health Data Science, Graduate School of Data Science, Yokohama City University, Kanagawa, Japan.
⁵ Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Department of Diabetes and Endocrinology, Juntendo University Urayasu Hospital, Chiba, Japan.
⁷ Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
⁸ Division of Diabetes, Metabolism and Endocrinology, Jikei University School of Medicine, Tokyo, Japan.
⁹ Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Aichi, Japan.
¹⁰ Department of Diabetes, Metabolism and Endocrinology, Tokyo Medical University, Tokyo, Japan.
¹¹ Department of Diabetes and Metabolic Diseases, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

^# Contributed equally.

PMID: 36636161
PMCID: PMC9829926
DOI: 10.1007/s13340-022-00605-x

Erratum in

Correction: A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.
Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Yamauchi T. Bouchi R, et al. Diabetol Int. 2023 Jul 14;14(4):446. doi: 10.1007/s13340-023-00644-y. eCollection 2023 Oct. Diabetol Int. 2023. PMID: 37781468 Free PMC article.

No abstract available

Keywords: Algorithm; Glycemic control; Pharmacotherapy; Type 2 diabetes.

PubMed Disclaimer

Figures

**Fig. 1**
Working concept of an algorithm for pharmacotherapy in T2DM

**Fig. 2**
Proposed algorithm for pharmacotherapy in T2DM

See this image and copyright information in PMC

Cited by

Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study.
Koto R, Yoshida S, Nakajima A, Miwa T, Nishimura R. Koto R, et al. Diabetol Int. 2024 Apr 13;15(3):632-637. doi: 10.1007/s13340-024-00718-5. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101189 Free PMC article.
Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Yasuda T, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H. Mita T, et al. Sci Rep. 2023 Sep 5;13(1):14649. doi: 10.1038/s41598-023-41036-1. Sci Rep. 2023. PMID: 37669959 Free PMC article.
Real-world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score-matched model analysis in Japan.
Horii T, Oikawa Y, Shimada A, Mihara K. Horii T, et al. J Diabetes Investig. 2023 Nov;14(11):1262-1267. doi: 10.1111/jdi.14062. Epub 2023 Jul 30. J Diabetes Investig. 2023. PMID: 37517084 Free PMC article.
PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, Braae UC, Major-Pedersen A, Suzuki R. Yabe D, et al. J Diabetes Investig. 2024 Nov;15(11):1566-1577. doi: 10.1111/jdi.14291. Epub 2024 Aug 22. J Diabetes Investig. 2024. PMID: 39172634 Free PMC article.
Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.
Yoneda C, Kobayashi J, Kuribayashi N. Yoneda C, et al. Diabetol Int. 2024 May 30;15(3):569-576. doi: 10.1007/s13340-024-00734-5. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101186 Free PMC article.

See all "Cited by" articles

References

1. Review Committee Survey on the Diagnostic Criteria for Diabetes Mellitus (SRCDCD) A report from the SCCDCD (Globally standardized version) Tonyobyou. 2012;55:485–504.
1. Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Matsuura T, Suzuki H, Kurose T, Yamada Y, Seino Y. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53(7):831–835. - PubMed
1. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49(6):975–980. - PubMed
1. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36(6):1789–1796. - PMC - PubMed
1. Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S, Tominaga Y. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 1997;20(10):1562–1568. - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

Affiliations

A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

Authors

Affiliations

Erratum in

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources